European Group for Blood and Marrow Transplantation registry studies in multiple myeloma

Seminars in Hematology

Volumn 38, Issue 3, 2001, Pages 219-225

  Björkstrand, Bo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ADULT; AGED; AUTOTRANSPLANTATION; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; FEMALE; GRAFT SURVIVAL; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0034893353     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90013-7     Document Type: Article

References (68)

1. Single versus double transplantation in myeloma: A prospective randomized trial of the Inter Groupe Francophone due Myelome (IFM)
2. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
3. Intensive combined therapy for previously untreated aggressive myeloma
4. Superiority of tandem autologous transplantation over standard therapy for previously untreated myeloma
5. A prospective, randomised trial of peripheral blood stem cells (PBSC) or marrow (BM) for patients undergoing allogeneic transplantation for hematological malignancies
6. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma
7. Syngeneic marrow transplantation in patients with multiple myeloma
8. Prognostic factors in autologous stem cell transplantation for multiple myeloma: An EBMT registry study
9. Autologous stem cell transplantation in multiple myeloma (MM) - The 2000 EBMT registry update
10. Autologous stem cell transplantation in multiple myeloma: Results of the European Group for Bone Marrow Transplantation
11. Double high-dose chemo-radiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma
12. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma - A retrospective case-matched study from the European Group for Blood and Marrow Transplantation
13. + cell selection of autologous blood stem cell grafts
14. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT)
15. EBMT registry results of autologous bone marrow and peripheral blood stem cell transplantation
16. 5489 Autotransplants in multiple myeloma - A registry study from the European Group for Blood and Marrow Transplantation (EBMT)
17. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation
18. Allogeneic bone marrow or peripheral blood stem cell transplantation
19. Allogeneic bone marrow transplantation for multiple myeloma. Results of a single centre
20. A randomized clinical trial comparing melphalan/prednisolone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: A Cancer and Leukemia Group B study
21. High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting
22. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells
23. A randomised trial of maintenance therapy with Intron-A following high dose melphalan and ABMT in myeloma
24. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
25. MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC Working Party on Leukaemia in Adults
26. + selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilisation in multiple myeloma
27. Identical-twin (syngeneic) marrow transplantation for hematologic cancers
28. Treatment of multiple myeloma (MM) with chemoradiotherapy and identical twin bone marrow transplantation
29. + enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation
30. Interferon-alpha treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients
31. Progress in haematopoietic stem cell transplantation for multiple myeloma
32. Progress in allogeneic hematopoietic stem cell transplantation for multiple myeloma
33. Syngeneic transplantation in multiple myeloma - A case-matched comparison with autologous and allogeneic transplantation
34. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-1993 and 1994-1998 at EBMT centres
35. Bone marrow transplantation in multiple myeloma: Report from the European Cooperative Group for Bone Marrow Transplantation
36. Allogeneic bone marrow transplantation in multiple myeloma
37. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma
38. + cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: A case controlled analysis
39. + selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: A randomised study from the EBMT
40. Blood and marrow transplantation activity in Europe 1997
41. +-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: Tumour cell contamination and outcome
42. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French registry on autologous transplantation in multiple myeloma
43. Increased incidence of cytomegalovirus disease after aurologous CD34-selected peripheral blood stem cell transplantation
44. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma
45. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma
46. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy
47. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma
48. Interferon theraphy in myelomatosis
49. Non-myeloablative peripheral blood stem cell (PBSC) allografts following cytoreductive autotransplants for treatment of multiple myeloma (MM)
50. Identical twin marrow transplantation in multiple myeloma
51. Dose-intensive melphalan with stem cell support (Mel 100) is superior to standard treatment in elderly myeloma patients
52. Effect of complete response on outcome following autologous stem cell transplantation for myeloma
53. Allogeneic bone marrow transplant for multiple myeloma
54. + peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma
55. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation
56. Prognostic value of cytogenetics in multiple myeloma
57. Age is not a prognostic variable with autotransplants for multiple myeloma
58. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over
59. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants
60. Predicting long term (≥5 yr) event-free survival (EFS) in multiple myeloma (MM) following tandem autotransplants (TT)
61. Graft-versus-myeloma effect: Proof of principle
62. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma
63. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma
64. Allogeneic bone marrow transplantation for multiple myeloma
65. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: A randomized study
66. A meta-analysis of trials of interferon as therapy for myeloma
67. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: A randomized clinical trial from the Myeloma Group of Central Sweden
68. Natural interferon-α in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: A randomized study from the Myeloma Group of Central Sweden